Syntara Ltd (ASX:SNT)
A$ 0.056 0.006 (12%) Market Cap: 68.66 Mil Enterprise Value: 65.37 Mil PE Ratio: 0 PB Ratio: 14.00 GF Score: 0/100

Pharmaxis Ltd at MST Access Biotech 'Hidden Gems' Forum Transcript

Jul 20, 2023 / NTS GMT
Release Date Price: A$0.057 (+5.56%)
Chris Kallos
MST Access Services Pty Limited - Moderator

Pharmaxis is a signal based company that has developed a unique and novel proprietary chemistry around an enzyme system involved with fibrosis. Fibrosis is associated with a whole raft of diseases not the least of which is bone marrow cancer, which is one of the lead time programs and scarring.

And with that, I'll hand it over to Gary to walk us through the presentation. Thank you, Gary.

Gary Phillips
Pharmaxis Ltd - CEO

Thanks very much, Chris. And yeah, so let me just get my presentation up and ready to go, there we are. So yes, I think, Chris, you do labeled this session hidden gems, I think you said that Pharmaxis is somebody it's hiding in plain sight, I would guess.

So for those of you who are not familiar with us, I mean, we've gone through a couple of iterations in our history, but the place we've been is a really exciting one, and we've made some quite dramatic steps forward in the last -- just in the last few months actually.

So we are rather unique in the Australian

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot